Clinical trialNCT01431339CompletedPhase 3Interventional

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

SponsorDurata Therapeutics Inc., an affiliate of Allergan plcEnrollment739AbscessCellulitisSurgical Site InfectionWound Infection

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael Dunne, MD
Durata Therapeutics Inc., an affiliate of Allergan plc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

137 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bulgaria

Durata Study Site
Pleven, Bulgaria
Durata Study Site
Plovdiv, Bulgaria
Durata Study Site
Sevlievo, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria

Estonia

Durata Clinical Site
Kohtla-Järve, Estonia
Durata Study Site
Kohtla-Järve, Estonia
Durata Clinical Site
Tallinn, Estonia
Durata Clinical Site
Tallinn, Estonia
Durata Study Site
Tartu, Estonia

Hungary

Durata Clinical Site
Budapest, Hungary
Durata Study Site
Budapest, Hungary
Durata Study Site
Debrecen, Hungary
Durata Clinical Site
Kaposvár, Hungary
Durata Clinical Site
Pécs, Hungary
Durata Clinical Site
Szeged, Hungary
Durata Study Site
Veszprém, Hungary

Israel

Durata Clinical Site
Haifa, Israel
Durata Study Site
Jerusalem, Israel
Durata Clinical Site
Kfar Saba, Israel
Durata Clinical Site
Petah Tikva, Israel
Durata Study Site
Petah Tikva, Israel
Durata Clinical Site
Ramat Gan, Israel
Durata Study Site
Tel Aviv, Israel

Latvia

Durata Clinical Site
Daugavpils, Latvia
Durata Clinical Site
Liepāja, Latvia
Durata Clinical Site
Riga, Latvia
Durata Study Site
Riga, Latvia
Durata Study Site
Rēzekne, Latvia
Durata Clinical Site
Ventspils, Latvia

Lithuania

Durata Clinical Site
Kaunas, Lithuania
Durata Clinical Site
Kauno M. Sav, Lithuania
Durata Clinical Site
Klaipėda, Lithuania
Durata Clinical Trial
Vilnius, Lithuania
Durata Clinical Site
Šiauliai, Lithuania

Romania

Durata Clinical Site
Bucharest, Romania
Durata Clinical Trial
Bucharest, Romania
Durata Study Site
Bucharest, Romania

97 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2011
Primary completion: 30 Nov 2012
Completion: 31 Dec 2012
Last update posted: 12 Feb 2014
Registered enrollment: 739
Registry id: NCT01431339

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.